RIKEN Center: Researcher Obokata Will Participate In STAP Verification Tests
This article was originally published in PharmAsia News
Japanese research center RIKEN will allow the researcher Haruko Obokata to participate in verification tests regarding the existence of STAP cells on July 1, the center recently announced.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.